Perimeter Medical Imaging AI, Inc., a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the initiation of a multi-center, randomized, two-arm pivotal clinical trial to evaluate its Perimeter B-Series OCT with ImgAssist AI for use during breast conservation surgery. The first patient procedures were performed by Richard E. Fine, MD and Michael Berry, MD, leading breast surgeons based out of the Margaret West Comprehensive Breast Center in Germantown, Tennessee.

Jeremy Sobotta, Perimeter's Chief Executive Officer said that the initiation of this pivotal trial marks another milestone in their ATLAS AI project and an important step in the clinical development of breakthrough-device-designated Perimeter B-Series OCT with AI assisted software, which represents the next generation of commercially available flagship Perimeter S-Series OCT. The hope is that clinical data generated from this study will provide supporting evidence that their technology can help breast cancer physicians improve outcomes for patients and potentially reduce the burden of additional costs within the healthcare system.